On Monday, Moderna Inc (MRNA.O) said its COVID-19 vaccine which generated a strong immune response in children aged six to 11 years and that it plans to submit the data to global regulators soon. Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and